Oncology Data Advisor
Enzalutamide Approved for Nonmetastatic CSPC With Biochemical Recurrence: Stephen Freedland, MD
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:13:34
- More information
Informações:
Synopsis
The FDA recently granted approval to enzalutamide (enza) for the treatment of nonmetastatic castration-sensitive prostate cancer (nmCRPC) with biochemical recurrence, based on the results of the phase 3 EMBARK trial. Following the approval, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, co-lead investigator of the trial, sat down to share more about its significance for patients with high-risk prostate cancer and biochemical recurrence.
